American Journal of Cardiovascular Drugs

, Volume 19, Issue 2, pp 223–224 | Cite as

Authors’ Reply to Rana et al. “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”

  • Usha K. Misra
  • Jayantee Kalita
  • Mritunjai Kumar
  • Methil PradeepEmail author
Letter to the editor


Compliance with Ethical Standards


No external funding was used in the preparation of this reply.

Conflict of interest

Usha Misra, Jayantee Kalita, Mritunjai Kumar, and Methil Pradeep have no conflicts of interest that might be relevant to the content of this reply.


  1. 1.
    Rana PB, Jacob NT, Toms T, Bhure S. Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”. Am J Cardiovasc Drugs 2019.
  2. 2.
    Ramakrishnan TC, Kumaravelu S, Narayan SK, Buddha SS, Murali C, Majeed PH, et al. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label. Multicenter Trials. Am J Cardiovasc Drugs. 2018;18:387–95.CrossRefGoogle Scholar
  3. 3.
    Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 1994;25:2072–8.CrossRefGoogle Scholar
  4. 4.
    Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185:154–9.CrossRefGoogle Scholar
  5. 5.
    Haley EC, Lyden PD, Johnston KC, Hemmen TM. TNK in Stroke Investigators and others. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36:607–12.CrossRefGoogle Scholar
  6. 6.
    Haley EC, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, for the tenecteplase in stroke Investigators, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707–11.CrossRefGoogle Scholar
  7. 7.
    Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.CrossRefGoogle Scholar
  8. 8.
    Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.CrossRefGoogle Scholar
  9. 9.
    Bivard A, Huang X, Levi CR, Spratt N, Campbell BC, Cheripelli BK, et al. Tenecteplase in ischemic stroke offers improved recanalization Analysis of 2 trials. Neurology. 2017;89:62–7.CrossRefGoogle Scholar
  10. 10.
    Campbell BC, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–82.CrossRefGoogle Scholar
  11. 11.
    Baird AE. Paving the way for improved treatment of acute stroke with tenecteplase. N Engl J Med. 2018;378:1635–6.CrossRefGoogle Scholar
  12. 12.
    Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of NeurologySanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia
  2. 2.Department of NeurologyAll India Institute of Medical SciencesRaipurIndia
  3. 3.K.G. Hospital and Post Graduate InstituteCoimbatoreIndia

Personalised recommendations